The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: Urgent questions and difficult answers

Biomedical Papers

Volumn 153, Issue 1, 2009, Pages 5-12

  Stiborova, Marie ^a   Frei, Eva ^b   Arlt, Volker M ^c   Schmeiser, Heinz H ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aristolochic acid; Aristolochic acid nephropathy (AAN); Balkan endemic nephropathy (BEN); Metabolism; Renal injury; Urothelial cancer

Indexed keywords

ANIMALIA; MUS; RODENTIA;

ARISTOLOCHIC ACID; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ANIMAL; ARTICLE; BIOTRANSFORMATION; CHEMICALLY INDUCED DISORDER; DNA ADDUCT; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; KIDNEY; KIDNEY DISEASE; METABOLISM; MOUSE; URINARY TRACT CANCER;

ANIMALS; ARISTOLOCHIC ACIDS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA ADDUCTS; ENZYME ACTIVATION; HUMANS; KIDNEY; KIDNEY DISEASES; MICE; NADPH-FERRIHEMOPROTEIN REDUCTASE; UROLOGIC NEOPLASMS;

EID: 70149117027     PISSN: 12138118     EISSN: 12138118     Source Type: Journal    
DOI: 10.5507/bp.2009.001     Document Type: Article

References (54)

1. IARC (International Agency for Research on Cancer). Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risks Hum. 2002; 82.
2. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Valdervelde D, Verbeelen D, Vanhaelen-Fastre B, Vanhaelen M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341:387-91.
3. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs. Lancet 1994; 343:174.
4. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996; 56:2025-28.
5. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002; 17:265-77.
6. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74:158-69
7. Gillerot G, Jadoul M, Arlt VM, van Ypersele de Strihou C, Schmeiser HH, But PHH, Bieler CA, Cosyns J-P. Aristolochic acid nephropathy in a Chinese patient: time to abandon the term Chinese herbs nephropathy? Am J Kidney Dis 2001; 38:E26.
8. Cosyns JP. Aristolochic acid and Chinese herbs nephropathy: a review of the evidence to date. Drug Safety 2003; 26:33-48.
9. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petřin M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associ- ated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342:1686-92.
10. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001; 358:1515-6.
11. Arlt VM, Alunni-Perret M, Quatrehomme G, Ohayon P, Albano L, Gaid H, Michiels JF, Meyrier A, Cassuto E, Wiessler M, Schmeiser HH, Cosyns J-P. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer 2004; 111: 977-80.
12. Gold LS, Slone TH. Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. N Engl J Med 2003; 349:1576-7.
13. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L, Cogliano V., WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part A: pharmaceuticals. Lancet Oncol 2009; 10:13-4.
14. Ivic M. Etiology of endemic nephropathy. Lijec Vjesn 1969; 91:1273-81.
15. Tatu CA, Oren WH, Finkelman RB, Feder GL. The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect 1998; 106:689-700.
16. Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Vdovic S, Schmeisr HH, Cosyns JP. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 2002: 101:500-2.
17. Stiborová M, Patočka J, Frei E, Schmeiser HH. Biochemistry and toxicological aspects of etiology of Balkan endemic nephropathy [in Czech]. Chem Listy 2005; 99:782-8.
18. Stefanovic V., Toncheva D, Atanasova S, Polenakovic M. Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am J Nephrol 2006; 26:1-11.
19. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky R, Goodenough A K, Rieger R, Vukelic M, Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy, Proc Natl Acad Sc USA 2007; 104:12129-34.
20. Nedelko T, Arlt VM, Phillips DH, Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 2009; 124:987-90.
21. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelakovic B. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J 2005; 46:116-25.
22. Nortier JL, Schmeiser HH, Martinez MCM, Arlt VM, Vervaet C, Garbar CH, Daelemans P, Vanherweghem JL. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. Nephrol Dial Transplant 2003; 18:426-28.
23. Qi X, Cai Y, Gong L, Liu L, Chen F, Xiao Y, Wu X, Li Y, Xue X, Ren J. Role of mitochondrial permeability transition in human renal tubuar epithelial cell death induced by aristolochic acid. Toxicol Appl Pharmacol 2007; 222:105-10.
24. Arlt VM, Stiborová M, vom Brocke J, Simoes ML, Lord GM, M. Stiborová, E. Frei, V. M. Arlt, H. H. Schmeiser Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. Aristolochic acid mutagenesis: molecular clues to the etiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogensis 2007; 28: 2253-61.
25. Stiborová M, Frei E, Arlt VM, Schmeiser HH. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 2008; 658:55-67.
26. Lebeau C, Arlt VM, Schmeiser HH, Boom A, Verroust PJ, Devuyst O, Beauwens R. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int 2001; 60:1332-42.
27. Lebeau C, Debelle FD, Arlt VM, Pozdzik A, De Prez EG, Phillips DH, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant 2005; 20:2321-32.
28. Stemmer K, Ellinger-Ziegelbauer H, Ahr HJ, Dietrich DR. Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis. Cancer Res 2007; 67:4052-68.
29. Simões ML, Hockley SL, Schwerdtle T, da Costa GG, Schmeiser HH, Phillips DH, Arlt VM. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. Toxicol Appl Pharmacol 2008; 232:86-98.
30. Schmeiser HH, Stiborovà M, Arlt VM. Chemical and molecular basis of the carcinogenicity of Aristolochia plants.Curr Opin Drug Discov Devel 2009; 12:141-8.
31. Meinl W, Pabel U, Osterloh-Quitroz H, Hengstler JG, Glatt H. Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer 2006; 118:1090-7.
32. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 2004; 43:e11-17.
33. Chan W, Luo H-B, Zheng Y, Cheng Y-K, Cai Z. Investigation of the metabolism and reductive activation of carcinogenic aristolochic acid in rats, Drug Metab Dispos 2007; 35:866-74.
34. Stiborová M, Frei E, Sopko B, Wiessler M, Schmeiser HH. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 2002; 23:617-25.
35. Stiborová M, Frei E, Sopko B, Sopková K, Marková V, Laňková M, Kumstýřová T, Wiessler M, Schmeiser HH. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aris- tolochic acid: evidence for reductive activation by human NAD(P) H:quinone oxidoreductase. Carcinogenesis 2003; 24:1695-703.
36. Stiborová M, Frei E, Hodek P, Wiessler M, Schmeiser HH. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 2005; 113:189-97.
37. Stiborová M, Frei E, Wiessler M, Schmeiser HH. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochrome P450 1A1 and 1A2. Chem Res Toxicol 2001; 14:1128-37.
38. Stiborová M, Sopko B, Hodek P, Frei E, Schmeiser HH, Hudeček J. The binding of aristolochic acid I to the active site of human cyto- chromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett 2005; 229:193-204.
39. Stiborová M, Hájek M, Frei E, Schmeiser HH. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen Physiol Biophys 2001; 20:375-92.
40. 32P-postlabeling analysis of DNA adduct formation. Mutat Res 2001; 493:149-60.
41. Toncheva D I, von Ahsen N, Atanasova SY, Dimitrov TG, The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused 11 by aristolochic acid: Urgent questions and difficult answers Armstrong VM, Oellerich M. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol 2004; 17:384-89.
42. 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 2006; 34:1122-27.
43. Stiborová M, Frei E, Breuer A, Bieler CA, Schmeiser HH. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp Toxic Pathol 1999: 51:421-27.
44. Chan W, Cu L, Xu G, Cai Z. Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatog- raphy/tandem mass spectrometry, Rapid Commun. Mass Spectrom 2006; 20:1755-60.
45. Šístková J, Hudeček J, Hodek P, Frei E, Schmeiser HH, Stiborová M. Human cytochromes P450 1A1 and 1A2 participate in detoxica- tion of carcinogenic aristolochic acid. Neuro Endocrinol Lett 2008; 29:733-7.
46. 46. Toncheva D. Genetic studies in BEN and associated urothelial cancers. Coll. Antropol 2006; 30Suppl 1:34.
47. Xiao Y, Ge M, Xue X, Wang H, Wu X, Li L, Liu L, Qi X, Zhang Y, Li Y, Xie T, Gu J, Ren J. Detoxication role of hepatic cytochrome P450s in the kidney toxicity induced by aristolochic acid. Kidney Int 2008; 73:1231-9.
48. Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH, Phillips DH. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidore- ductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 2005; 65:2644-52.
49. Arlt VM, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Stiborova M. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett 2006; 234:220-31.
50. Arlt VM, Stiborová M, Henderson CJ, Thiemann M, Frei E, Aimová D, Singhs R, da Costa GG, Schmitz OJ, Farmer PB, Wolf CR, Phillips DH. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 2008; 29:656-65.
51. Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudeček J, Phillips DH, Frei E. Role of hepatic cy- tochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 2008; 226:318-27.
52. Xue X, Xiao Y, Zhu H, Wang H, Liu Y, Xie T, Ren J. Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol Dial Transplant 2008; 23:3074-81.
53. Reynisson J, Stiborová M, Martínek V, Gamboa da Costa G, Phillips DH, Arlt VM. Mutagenic potential of nitrenium ions of nitrobenzanthrones: correlation between theory and experiment. Environm Mol Mutagenesis 2008; 49:659-67.
54. Stiborová M, Frei E, Schmeiser HH. Biotransformation enzymes in development of renal injury and urothelial cancer cause by aristolochic acid. Kidney Int 2008; 73:1209-11.